OncoSec’s Cancer Clinical Trial Strategy Featured in BioWorld Magazine

OncoSec’s Cancer Clinical Trial Strategy Featured in BioWorld Magazine

15 August 2011,   By ,   0 Comments

Article Highlights OncoSec’s Entry Into Three Phase II Trials for Skin Cancer

SAN DIEGO, CA, August 15, 2011 — OncoSec Medical Incorporated (OTCBB: ONCS), which is developing its advanced-stage OMS ElectroOncology therapies to treat solid tumor cancers, announced today that a profile of the company and its pipeline of oncology therapies is featured in the most recent issue of BioWorld, one of the most widely read publications in the pharma and biotech industries. The article can be purchased at www.bioworld.com.

The publication noted that: “The San Diego-based biotech has yet to celebrate its first anniversary, but its lead electro immunotherapy candidate, DNA IL-12, is heading into three Phase II trials for melanoma, Merkel cell carcinoma and cutaneous T-cell lymphoma (CTCL). The company attributes its enviable maturity to its March spin-out from Inovio Pharmaceuticals Inc., of Blue Bell, Pa. The move allowed Inovio to focus on DNA vaccines, while giving OncoSec the opportunity to develop electrochemical and cytokine-based immune therapies for treating solid tumors via electroporation delivery.”

A previous Phase I trial provided further evidence that a DNA plasmid encoded to produce IL-12 delivered by electroporation into melanoma lesions induces responses to known and novel antigens, resulting in regression of local treated lesions as well as distant untreated lesions The link below provides further information on this trial:(http://www.oncosec.com/news/oncosec-electroimmunotherapy-shows-systemic-effects-of-metastatic-melanoma-tumor-in-more-than-50-percent-of-patients).

OncoSec’s President and CEO, Punit Dhillon said, “We are pleased to receive recognition from a global biotech publication for OncoSec’s lead pipeline immunotherapeutic product. We look forward to reporting additional progress from our Phase II skin cancer trials in Q4.”

About BioWorld Today®

BioWorld® Today, the news source of record for the biotechnology industry, is read by biotechnology professionals worldwide for its hard-hitting, objective news reporting. BioWorld Today is delivered via e-mail every business morning, and is also found exclusively online at www.bioworld.com. The BioWorld online web site has been internationally recognized as the most comprehensive resource for strategic biotechnology news and information available today.

About OncoSec Medical Inc.

OncoSec Medical (OTCBB: ONCS) develops novel ElectroOncology therapies that combine its proprietary electroporation delivery technology with a chemotherapeutic or novel DNA-based immunotherapeutics. Targeted local delivery of these agents is designed to achieve selective destruction of cancerous tumors while sparing healthy normal tissue, resulting in improved functional, cosmetic and quality of life outcomes. These therapies have achieved validating safety and efficacy data in early and late stage clinical studies of over 400 cancer patients. OncoSec’s clinical programs include three Phase II clinical trials. More information is available at www.oncosec.com.

* * *
This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such “forward looking statements.” Forward looking statements are based on management’s current preliminary expectations and are subject to risks and uncertainties which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition and market conditions. These and additional risks and uncertainties are more fully described in OncoSec’s filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward looking statements which speak only as of the date they are made. OncoSec disclaims any obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.


Real Time Web Analytics